SDCCAG8 Antibody

What is SDCCAG8 and why is it important in scientific research?

SDCCAG8 (serologically defined colon cancer antigen 8), also known as CCCAP (centrosomal colon cancer autoantigen protein) or NY-CO-8, is a 713 amino acid cytoplasmic protein with a molecular weight of approximately 83 kDa. This protein plays crucial roles in establishing cell polarity, epithelial lumen formation, and ciliogenesis. SDCCAG8 has gained research significance due to its association with nephronophthisis-related ciliopathies (NPHP-RC), a recessive disorder characterized by dysplasia or degeneration of the kidney, retina, and cerebellum. The protein localizes to centrioles and directly interacts with oral-facial-digital syndrome 1 (OFD1), making it an important target for studying ciliopathies and centrosomal function .

What types of SDCCAG8 antibodies are available for research applications?

Researchers have access to both polyclonal and monoclonal SDCCAG8 antibodies for various experimental applications:

When selecting an antibody, consider your target species, application requirements, and whether polyclonal (broader epitope recognition) or monoclonal (higher specificity for a single epitope) would better suit your experimental needs .

What is the subcellular localization of SDCCAG8 and how does this affect antibody selection?

SDCCAG8 primarily localizes to centrioles and plays a role in ciliary formation. It exists as a homodimer and contains eight predicted coiled-coil motifs divided into three regions: N-terminal (1-294 aa), middle (286-541 aa), and C-terminal (533-713 aa). The subcellular localization has important implications for antibody selection:

• For centrosomal localization studies: Choose antibodies validated for immunofluorescence that have demonstrated centrosomal staining patterns

• For studies of C-terminal function: Select antibodies targeting the C-terminal region (533-713 aa), which has been shown to be crucial for proper centrosomal localization and cilia formation

• For protein interaction studies: Consider antibodies that don't interfere with known protein-protein interaction sites, particularly those involving OFD1 or ICK/MAK kinases

Immunofluorescence microscopy with SDCCAG8 antibodies typically shows characteristic centrosomal staining patterns, with prominent labeling at the base of primary cilia in ciliated cells .

What are the optimal immunohistochemistry (IHC) conditions for SDCCAG8 antibody applications?

For successful SDCCAG8 detection in tissue sections using IHC, consider the following protocol optimization parameters:

Antigen Retrieval:

• Primary recommendation: TE buffer pH 9.0

• Alternative: Citrate buffer pH 6.0

Antibody Dilutions:

• Polyclonal antibodies: 1:50-1:500 range (Proteintech 13471-1-AP)

• Monoclonal antibodies: 1:50-1:500 range (Proteintech 66284-1-Ig)

• Assay Genie PACO03368: 1:100-1:300

Positive Controls:

• Mouse brain tissue has been validated for SDCCAG8 detection

• Human kidney tissue shows reliable SDCCAG8 expression

Technical Notes:

• Titration in your specific testing system is strongly recommended for optimal results

• Fixation conditions may significantly impact epitope availability; consider testing multiple fixation protocols if signal is suboptimal

• For phosphorylated-SDCCAG8 detection, phosphatase inhibitors should be included throughout sample preparation

What are the recommended western blot conditions for detecting SDCCAG8?

For optimal western blot detection of SDCCAG8 (expected molecular weight: 83 kDa), follow these methodological considerations:

Sample Preparation:

• Include phosphatase and protease inhibitors in lysis buffers

• Heat samples at 95°C for 5 minutes in standard reducing SDS-PAGE loading buffer

Gel Percentage and Transfer Conditions:

• 8-10% SDS-PAGE gels are recommended for optimal separation

• Semi-dry or wet transfer systems both work effectively

Antibody Dilutions:

• Monoclonal antibodies: 1:500-1:2000 (Proteintech 66284-1-Ig)

• NovoPro monoclonal: 1:500-1:5000

Positive Controls:

• HEK-293 cells show reliable expression

• THP-1 cells are also recommended as positive controls

• COLO 320 cells have been validated for western blot applications

Detection Systems:

• Both chemiluminescent and fluorescent secondary detection systems are compatible

• For low expression levels, enhanced chemiluminescent substrates are recommended

How can SDCCAG8 antibodies be used effectively in immunofluorescence applications?

For successful immunofluorescence detection of SDCCAG8 in cultured cells or tissue sections:

Cell Fixation Options:

• 4% paraformaldehyde (10-15 minutes at room temperature)

• Methanol fixation (-20°C for 10 minutes) can enhance centrosomal epitope accessibility

Permeabilization:

• 0.1-0.5% Triton X-100 in PBS (5-15 minutes at room temperature)

Blocking and Antibody Conditions:

• Block with 5% normal serum from secondary antibody host species

• Primary antibody dilutions: 1:400-1:1600 (Proteintech 13471-1-AP)

• Incubation: Overnight at 4°C or 1-2 hours at room temperature

Co-staining Recommendations:

• Anti-acetylated α-tubulin for ciliary axoneme visualization

• Anti-γ-tubulin for centrosome/basal body identification

• Anti-OFD1 for co-localization studies at centrioles

Technical Notes:

• HeLa cells have been validated for IF applications with SDCCAG8 antibodies

• When studying ciliary dynamics, serum starvation (24-48 hours) is recommended to induce ciliogenesis prior to fixation

How can SDCCAG8 antibodies be used to study ciliopathies and related disorders?

SDCCAG8 mutations are associated with nephronophthisis-related ciliopathies (NPHP-RC) and Bardet-Biedl syndrome (BBS16). Researchers investigating these conditions can employ SDCCAG8 antibodies in several advanced applications:

Patient Sample Analysis:

• Compare SDCCAG8 expression, localization, and post-translational modifications between patient and control samples using validated antibodies

• Correlate protein abnormalities with specific SDCCAG8 mutations

Animal Model Validation:

• Use antibodies to confirm phenotypic effects in SDCCAG8 mutant models

• The SDCCAG8ΔC/ΔC mouse model with C-terminal truncation can be studied using N-terminal targeting antibodies to assess protein expression and localization

Functional Studies:

• Combine with ciliary markers to assess ciliogenesis defects

• Evaluate centrosomal localization in conjunction with SDCCAG8 knockdown/mutation

• Studies have demonstrated that SDCCAG8 knockdown using shRNA (particularly Sdccag8-shRNA2 and Sdccag8-shRNA3) significantly decreases ciliated cell numbers and cilia length in NIH-3T3 cells, which can be rescued by wild-type SDCCAG8 expression

Molecular Pathway Analysis:

• Investigate SDCCAG8 interactions with ICK/CILK1 and MAK, which are essential for ciliary protein trafficking and cilia length regulation

• Assess Hedgehog signaling pathway activity, which requires intact primary cilia for activation

What protein-protein interactions can be studied using SDCCAG8 antibodies?

SDCCAG8 participates in several critical protein interactions that can be investigated using co-immunoprecipitation and proximity ligation assays with SDCCAG8 antibodies:

Validated Interacting Partners:

• OFD1 (Oral-facial-digital syndrome 1) - direct interaction at centrioles

• ICK/CILK1 (Intestinal cell kinase) - interaction confirmed by endogenous co-immunoprecipitation

• MAK (Male germ cell-associated kinase) - interaction detected with SDCCAG8

• RABEP2 - SDCCAG8 mediates its centrosomal localization critical for ciliogenesis

Methodological Approach:

• Co-immunoprecipitation can be performed using anti-SDCCAG8 antibodies in HEK293T cell extracts, which has successfully detected endogenous ICK in immunoprecipitates

• Domain mapping experiments have shown that the C-terminal region of SDCCAG8 (533-713 aa) is crucial for interaction with ICK/CILK1 and MAK

Technical Considerations:

• Use mild lysis conditions (e.g., 1% NP-40 or 0.5% Triton X-100) to preserve protein-protein interactions

• Pre-clear lysates with protein A/G beads before immunoprecipitation to reduce non-specific binding

• Include appropriate controls (IgG control, input samples)

How can SDCCAG8 antibodies be used to study the functional domains of the protein?

SDCCAG8 contains distinct functional domains that can be investigated using domain-specific antibodies or in combination with domain deletion/mutation constructs:

Key Functional Regions:

• N-terminal region (1-294 aa)

• Middle region (286-541 aa) containing coiled-coil motifs

• C-terminal region (533-713 aa) - crucial for centrosomal localization and protein interactions

Experimental Approaches:

• Domain deletion rescue experiments: Studies have shown that full-length human SDCCAG8 (hSDCCAG8-FL) can rescue cilia formation defects caused by Sdccag8 knockdown, while the N-terminal to middle region construct (hSDCCAG8-NM, 1-541 aa) lacking the C-terminus cannot

• Immunofluorescence with antibodies targeting different domains can reveal differential localization patterns

• C-terminal truncation models (such as the Sdccag8ΔC/ΔC mouse with Arg537Stop mutation) can be analyzed with N-terminal specific antibodies to study domain-specific functions

Technical Notes:

• When studying domain-specific functions, consider using antibodies targeting epitopes outside the domain of interest to avoid interference

• For complementation studies, ensure that epitope tags don't interfere with domain functionality

• RT-PCR analysis can confirm expression levels of truncated constructs

How can researchers address common issues with SDCCAG8 antibody specificity?

Ensuring antibody specificity is critical for reliable SDCCAG8 detection. Consider these approaches when validating or troubleshooting specificity issues:

Validation Methods:

• Knockout/Knockdown Controls:

  • Use SDCCAG8 knockout cell lines or SDCCAG8 shRNA-treated cells (Sdccag8-shRNA2 and Sdccag8-shRNA3 have been validated) as negative controls

  • Compare with wild-type or scrambled shRNA controls

• Peptide Competition:

  • Pre-incubate the antibody with immunizing peptide to block specific binding

  • Immunizing peptides may be available for some commercial antibodies (e.g., synthesized peptide derived from the C-terminal region of human NY-CO-8 for PACO03368)

• Multiple Antibody Validation:

  • Compare results from different antibodies targeting distinct epitopes

  • Both polyclonal (e.g., Proteintech 13471-1-AP) and monoclonal (e.g., Proteintech 66284-1-Ig) antibodies are available

Common Specificity Issues:

• Cross-reactivity with related proteins

• Non-specific binding in certain tissues

• Batch-to-batch variability (especially with polyclonal antibodies)

• Species-specific differences in epitope conservation

What are the critical controls needed when using SDCCAG8 antibodies in different applications?

Proper experimental controls are essential for reliable interpretation of SDCCAG8 antibody results:

Western Blot Controls:

• Positive Controls: HEK-293 cells, COLO 320 cells, THP-1 cells (validated for showing 83 kDa SDCCAG8 band)

• Loading Controls: Housekeeping proteins appropriate for your experimental context

• Molecular Weight Marker: To confirm the expected 83 kDa band

• Secondary Antibody Only: To identify non-specific binding

Immunocytochemistry/Immunofluorescence Controls:

• Positive Controls: HeLa cells have been validated for IF applications

• Negative Controls: Secondary antibody only

• Colocalization Markers: Anti-acetylated α-tubulin (ciliary marker), anti-γ-tubulin (centrosomal marker)

• Knockdown Validation: Cells treated with Sdccag8-shRNA constructs

Immunohistochemistry Controls:

• Positive Controls: Mouse brain tissue and human kidney tissue have been validated

• Negative Controls: Normal IgG from the same species as primary antibody

• Antigen Retrieval Assessment: Compare different retrieval methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0)

How should researchers interpret conflicting data from different SDCCAG8 antibodies?

When faced with discrepancies between different SDCCAG8 antibodies, consider these methodological approaches:

Potential Sources of Discrepancy:

• Epitope Differences:

  • Different antibodies target distinct regions of SDCCAG8

  • Some epitopes may be masked by protein interactions or post-translational modifications

  • The C-terminal region (533-713 aa) is particularly important for protein function

• Antibody Format Differences:

  • Polyclonal antibodies recognize multiple epitopes but may have more background

  • Monoclonal antibodies offer higher specificity but might miss some isoforms

• Technical Variables:

  • Sample preparation methods affect epitope availability

  • Fixation conditions can significantly impact immunostaining patterns

  • Antibody concentrations may require optimization for each application

Resolution Approaches:

• Use multiple antibodies targeting different epitopes

• Include appropriate positive and negative controls

• Consider the specific application requirements and optimize conditions accordingly

• Consult published validation data from antibody manufacturers

How can SDCCAG8 antibodies contribute to emerging research on ciliopathies?

SDCCAG8 antibodies offer valuable tools for advancing ciliopathy research in several emerging areas:

Multi-Organ Pathology Investigation:

• SDCCAG8 mutations are associated with ciliopathies affecting multiple organs (kidney, retina, cerebellum)

• Antibodies enable tissue-specific expression and localization studies in different organ systems

• Correlating protein abnormalities with organ-specific phenotypes can reveal tissue-specific functions

Therapeutic Development Evaluation:

• Assess restoration of proper SDCCAG8 localization and function following experimental therapies

• Monitor changes in interacting protein networks after intervention

• Quantify ciliary formation and function in response to treatments

Molecular Pathway Elucidation:

• Further characterize the interactions between SDCCAG8, ICK/CILK1, and MAK in ciliary protein trafficking

• Investigate the relationship between SDCCAG8 and Hedgehog signaling pathway components

• Explore SDCCAG8's role in mediating RABEP2 centrosomal localization, which is critical for ciliogenesis

What novel applications are being developed for SDCCAG8 antibodies in research?

Several innovative applications for SDCCAG8 antibodies are emerging in the research landscape:

Live-Cell Imaging:

• Development of anti-SDCCAG8 nanobodies or non-interfering antibody fragments for live-cell studies

• Combination with fluorescent protein tagging to track SDCCAG8 dynamics during ciliary assembly and disassembly

High-Content Screening:

• Automated image analysis platforms using SDCCAG8 antibodies to screen for compounds affecting ciliogenesis

• Multi-parameter phenotypic profiling of genetic or chemical perturbations

Single-Cell Analysis:

• Application of SDCCAG8 antibodies in mass cytometry (CyTOF) or imaging mass cytometry for single-cell protein analysis

• Integration with transcriptomic data to correlate protein expression with gene expression patterns

Super-Resolution Microscopy:

• Utilizing SDCCAG8 antibodies with techniques like STORM, PALM, or STED to precisely map protein localization at the centrosome and ciliary base

• Multi-color super-resolution to visualize nanoscale protein interactions with partners like OFD1, ICK, and MAK